Ron Yu

2.5k total citations · 1 hit paper
32 papers, 1.7k citations indexed

About

Ron Yu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ron Yu has authored 32 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ron Yu's work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (7 papers) and Angiogenesis and VEGF in Cancer (4 papers). Ron Yu is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (7 papers) and Angiogenesis and VEGF in Cancer (4 papers). Ron Yu collaborates with scholars based in United States, South Korea and Spain. Ron Yu's co-authors include Tingjun Hou, Antonio González-Martı́n, Hans Wildiers, Melanie C. Smitt, Ian E. Krop, Patricia LoRusso, Abraham C.F. Leung, Sung‐Bae Kim, Jean-­Marc Ferrero and Branimir I. Šikić and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Ron Yu

30 papers receiving 1.7k citations

Hit Papers

Trastuzumab emtansine versus treatment of physician's cho... 2014 2026 2018 2022 2014 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
    2014 512 citations Ian E. Krop, Sung‐Bae Kim et al. The Lancet Oncology profile →

Peers

Ron Yu
Thomas Holbro Switzerland
T. Khanh United States
Xuewu Zhang China
Keng‐Hsueh Lan Taiwan
Mukesh K. Nyati United States
Paula R. Pohlmann United States
Scott A. Boerner United States
Wenle Xia United States
Edward M. Newman United States
Marie Prewett United States
Thomas Holbro Switzerland
Ron Yu
Citations per year, relative to Ron Yu Ron Yu (= 1×) peers Thomas Holbro

Countries citing papers authored by Ron Yu

Since Specialization
Citations

This map shows the geographic impact of Ron Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Yu more than expected).

Fields of papers citing papers by Ron Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Yu. The network helps show where Ron Yu may publish in the future.

Co-authorship network of co-authors of Ron Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Ron Yu. A scholar is included among the top collaborators of Ron Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron Yu. Ron Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Ron, et al.. (2022). A parallel sampling framework for model averaging: Application to dose response studies. Contemporary Clinical Trials. 123. 106957–106957.
2.
Yu, Ron & Jitendra Ganju. (2022). Sample size formula for a win ratio endpoint. Statistics in Medicine. 41(6). 950–963. 11 indexed citations
3.
4.
Rha, Sun Young, Pierfrancesco Tassone, Jorge Barriuso, et al.. (2014). A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. British Journal of Cancer. 111(4). 660–666. 75 indexed citations
5.
Weekes, Colin D., Muralidhar Beeram, Anthony W. Tolcher, et al.. (2014). A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Investigational New Drugs. 32(4). 653–660. 72 indexed citations
6.
Krop, Ian E., Sung‐Bae Kim, Antonio González-Martı́n, et al.. (2014). Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet Oncology. 15(7). 689–699. 512 indexed citations breakdown →
7.
Patnaik, Amita, Patricia LoRusso, Wells A. Messersmith, et al.. (2014). A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(5). 951–960. 61 indexed citations
8.
Yu, Ron, et al.. (2014). The other randomization — methods for labeling drug kits. Contemporary Clinical Trials. 38(2). 270–274. 3 indexed citations
9.
10.
Hoff, Paulo M., Josep Tabernero, Lin Shen, et al.. (2013). Pertuzumab, Trastuzumab and Chemotherapy in Her2-Positive Metastatic Gastric or Gastro-Oesophageal Junction Cancer: an International Phase III Study (Jacob). Annals of Oncology. 24. iv67–iv67. 9 indexed citations
11.
Kang, Yoon‐Koo, Sun Young Rha, Pierfrancesco Tassone, et al.. (2013). Pertuzumab Pharmacokinetics and Safety in Combination with Trastuzumab and Chemotherapy in Patients with Her2-Positive Advanced Gastric Cancer (Agc). Annals of Oncology. 24. iv19–iv19. 6 indexed citations
12.
Wong, Harvey, Nageshwar Budha, Kristina West, et al.. (2012). Dogs Are More Sensitive to Antagonists of Inhibitor of Apoptosis Proteins Than Rats and Humans: A Translational Toxicokinetic/Toxicodynamic Analysis. Toxicological Sciences. 130(1). 205–213. 13 indexed citations
13.
Singh, Mallika, Rafael Molina, Vidusha Devasthali, et al.. (2010). Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nature Biotechnology. 28(6). 585–593. 175 indexed citations
14.
Yu, Ron, et al.. (2008). Identification of Direct Target Genes Using Joint Sequence and Expression Likelihood with Application to DAF-16. PLoS ONE. 3(3). e1821–e1821. 7 indexed citations
15.
Xu, Jian, et al.. (2008). [Cytokine contents in single donor platelets during storage].. PubMed. 16(5). 1185–7.
16.
Bredel, Markus, Claudia Bredel, Dejan Juric, et al.. (2006). Tumor necrosis factor-α-induced protein 3 down-regulates nuclear factor-κB-mediated drug resistance in vitro and is a favorable clinical prognostic factor in human glioblastomas. Journal of Clinical Oncology. 24(18_suppl). 1508–1508. 1 indexed citations
17.
Yu, Ron & Eric Holmgren. (2006). Endpoints for agents that slow tumor growth. Contemporary Clinical Trials. 28(1). 18–24. 12 indexed citations
18.
DiMartino, Jorge, Norman J. Lacayo, Y. Ravindranath, et al.. (2006). Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 20(3). 426–432. 70 indexed citations
19.
Wang, Yan C., Dejan Juric, Brian San Francisco, et al.. (2005). Regional activation of chromosomal arm 7q with and without gene amplification in taxane‐selected human ovarian cancer cell lines. Genes Chromosomes and Cancer. 45(4). 365–374. 51 indexed citations
20.
Bredel, Markus, Claudia Bredel, Dejan Juric, et al.. (2005). Tumor Necrosis Factor-α–Induced Protein 3 As a Putative Regulator of Nuclear Factor-κB–Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas. Journal of Clinical Oncology. 24(2). 274–287. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Holbro Breakdown of academic impact, for papers by T. Khanh Breakdown of academic impact, for papers by Xuewu Zhang Breakdown of academic impact, for papers by Keng‐Hsueh Lan Breakdown of academic impact, for papers by Mukesh K. Nyati Breakdown of academic impact, for papers by Paula R. Pohlmann Breakdown of academic impact, for papers by Scott A. Boerner Breakdown of academic impact, for papers by Wenle Xia Breakdown of academic impact, for papers by Edward M. Newman Breakdown of academic impact, for papers by Marie Prewett
Rankless by CCL
2026